Agency Information Collection Activities: Submission for OMB Review; Comment Request, 29494-29495 [E9-14556]

Download as PDF 29494 Federal Register / Vol. 74, No. 118 / Monday, June 22, 2009 / Notices Dated: October 1, 2008. Janean Chambers, Reports Clearance Officer. Editorial Note: This document was received in the Office of the Federal Register on June 17, 2009. [FR Doc. E9–14543 Filed 6–19–09; 8:45 am] BILLING CODE 4184–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243. Proposed Project: Rapid HIV Testing Clinical Information Form for the Minority AIDS Initiative (MAI) for Ethnic and Racial Minorities at Risk for Substance Use and HIV/AIDS— Reinstatement The Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Treatment (CSAT), is requesting an OMB review and approval of the Minority AIDS Initiative (MAI) Rapid HIV Testing Clinical Information Form that will be utilized for ethnic and racial minority groups at risk for substance use and HIV/AIDS that are served by CSAT’s TCE–HIV grantees. The MAI Rapid HIV Testing Clinical Information Form would allow SAMHSA/CSAT to collect essential clinical information that will be used for quality assurance, quality performance, and product monitoring on approximately 30,000 rapid HIV test kits to be provided to ethnic and racial minority communities at no cost to the recipient provider organizations. The MAI Rapid HIV Testing Clinical Information Form would support quality of care, provide adequate clinical and product monitoring, and provide appropriate safeguards against fraud, waste and abuse of Federal funds. SAMHSA’s approach would avoid unnecessary delay in informing any person potentially adversely affected by a test kit recall or public health advisory. This program is authorized under section 509 of the Public Health Service (PHS) Act [42 U.S.C. 290bb–2]. The goals of SAMHSA’s MAI initiative are to: (1) Increase the access by racial and ethnic minority communities to HIV testing, prevention, care, and treatment services; (2) implement strategies and activities specifically targeted to the highest risk and hardest-to-serve populations; (3) reduce the stigma associated with HIV/ AIDS screening through outreach and education, and (4) establish collaborations or opportunities for programs and/or activities to be integrated. The target populations for the initiative are African Americans, Hispanic/Latinos, and other racial and ethnic minorities that are disproportionately impacted by the twin epidemics of HIV/AIDS and substance abuse. Since 1981 approximately 1.7 million people are estimated to have been infected with HIV in the U.S., and Number of respondents Form Responses/ respondent Hours/ response more than 1.1 million are estimated to be living with HIV/AIDS today. Racial and ethnic minorities have been disproportionately affected by HIV/ AIDS, and represent the majority of new AIDS cases (70%), new HIV infections (54%), prevalent HIV/AIDS cases (65%), and AIDS deaths (72%) (CDC, 2006). African Americans have been especially affected by HIV/AIDS. More than half of all new HIV infections and half of new AIDS diagnoses occur in African Americans despite their accounting for approximately 12% of the U.S. population. A similar impact exists among Latinos, who represent 14% of the U.S. population but account for 20% of estimated AIDS diagnoses. Together, Asian/Pacific Islanders and American Indian/Alaska Natives represent 1%– 2% of new AIDS diagnoses. The spread of HIV disease in the United States has been partly fueled by the use of illicit drugs. Injection drug use (IDU) is directly related to HIV transmission through the sharing of drug equipment. According to CDC’s latest report on 2006 rates, IDUs accounted for 12 percent of estimated new HIV infections. CDC’s historical trend analysis indicates that new infections have declined dramatically in this population over time and confirm the substantial evidence to date of success in reducing HIV infections among IDUs. Despite these declines, rates of HIV and AIDS continue to rise among certain groups including men who have sex with men, high risk heterosexual women and ethnic and racial minority groups due to non-IDU drugs and alcohol that interfere with judgment about sexual and other types of behaviors. The estimated hour burden is presented in the following table: Total hour burden Hourly wage cost ($) Total hour cost $) 20,000 1 .133 2,660 30.00 79,800 4,000 1 .133 532 30.00 15,960 Total .................................................. pwalker on PROD1PC71 with NOTICES MAI Rapid HIV Testing Clinical Information Form (at Entry) .............................. MAI Rapid HIV Testing Clinical Information Form (second test) ........................ 20,000 ........................ ........................ 3,192 ........................ 95,760 VerDate Nov<24>2008 16:55 Jun 19, 2009 Jkt 217001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1 Federal Register / Vol. 74, No. 118 / Monday, June 22, 2009 / Notices Written comments and recommendations concerning the proposed information collection should be sent by July 22, 2009 to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB’s receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202–395–6974. Dated: June 15, 2009. Elaine Parry, Director, Office of Program Services. [FR Doc. E9–14556 Filed 6–19–09; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting pwalker on PROD1PC71 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel. Attention Trajectories from 5 to 7 Years. Date: June 25, 2009. Time: 2 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6100 Executive Boulevard Room 5B01, Rockville, MD 20852. (Telephone Conference Call). Contact Person: Carla T. Walls, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892. (301) 435–6898. wallsc@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; VerDate Nov<24>2008 16:55 Jun 19, 2009 Jkt 217001 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: June 12, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–14497 Filed 6–19–09; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Diabetes, Obesity and Endocrine Disorders. Date: July 7–8, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Nancy Sheard, SCD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6046–E, MSC 7892, Bethesda, MD 20892, 301–435– 1154, sheardn@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel; Tumor Immunology and Genetic Pathways in Cancer. Date: July 9, 2009. Time: 10 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Malaya Chatterjee, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6192, PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 29495 MSC 7804, Bethesda, MD 20892, 301–451– 0131, chatterm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Gametes, Stem Cells, and Regeneration. Date: July 13, 2009. Time: 11 a.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Cathy Wedeen, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3213, MSC 7808, Bethesda, MD 20892, 301–435– 1191, wedeenc@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Special Topics in Aging and Development. Date: July 16, 2009. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: John Burch, PhD, Scientific Review Officer, National Institute of Health, Center for Scientific Review, 6701 Rockledge Drive, Room 3213, MSC 7808, Bethesda, MD 20892, 301–435–1019, burchjb@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–OD– 09–003 Challenge Grant Panel 11. Date: July 20–21, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Palomar Hotel, 2121 P Street, NW., Washington, DC 20037. Contact Person: Jerry L. Taylor, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5202, MSC 7846, Bethesda, MD 20892, 301–435– 1175, taylorje@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA OD– 09–003: Challenge Grants Panel Date: July 20–21, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Mandarin Oriental, 1330 Maryland Avenue, SW., Washington, DC 20024. Contact Person: Valerie Durrant, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 20892, (301) 435– 3554, durrantv@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) E:\FR\FM\22JNN1.SGM 22JNN1

Agencies

[Federal Register Volume 74, Number 118 (Monday, June 22, 2009)]
[Notices]
[Pages 29494-29495]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-14556]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Agency Information Collection Activities: Submission for OMB 
Review; Comment Request

    Periodically, the Substance Abuse and Mental Health Services 
Administration (SAMHSA) will publish a summary of information 
collection requests under OMB review, in compliance with the Paperwork 
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these 
documents, call the SAMHSA Reports Clearance Officer on (240) 276-1243.

Proposed Project: Rapid HIV Testing Clinical Information Form for the 
Minority AIDS Initiative (MAI) for Ethnic and Racial Minorities at Risk 
for Substance Use and HIV/AIDS--Reinstatement

    The Substance Abuse and Mental Health Services Administration's 
(SAMHSA) Center for Substance Abuse Treatment (CSAT), is requesting an 
OMB review and approval of the Minority AIDS Initiative (MAI) Rapid HIV 
Testing Clinical Information Form that will be utilized for ethnic and 
racial minority groups at risk for substance use and HIV/AIDS that are 
served by CSAT's TCE-HIV grantees. The MAI Rapid HIV Testing Clinical 
Information Form would allow SAMHSA/CSAT to collect essential clinical 
information that will be used for quality assurance, quality 
performance, and product monitoring on approximately 30,000 rapid HIV 
test kits to be provided to ethnic and racial minority communities at 
no cost to the recipient provider organizations. The MAI Rapid HIV 
Testing Clinical Information Form would support quality of care, 
provide adequate clinical and product monitoring, and provide 
appropriate safeguards against fraud, waste and abuse of Federal funds. 
SAMHSA's approach would avoid unnecessary delay in informing any person 
potentially adversely affected by a test kit recall or public health 
advisory. This program is authorized under section 509 of the Public 
Health Service (PHS) Act [42 U.S.C. 290bb-2].
    The goals of SAMHSA's MAI initiative are to: (1) Increase the 
access by racial and ethnic minority communities to HIV testing, 
prevention, care, and treatment services; (2) implement strategies and 
activities specifically targeted to the highest risk and hardest-to-
serve populations; (3) reduce the stigma associated with HIV/AIDS 
screening through outreach and education, and (4) establish 
collaborations or opportunities for programs and/or activities to be 
integrated.
    The target populations for the initiative are African Americans, 
Hispanic/Latinos, and other racial and ethnic minorities that are 
disproportionately impacted by the twin epidemics of HIV/AIDS and 
substance abuse. Since 1981 approximately 1.7 million people are 
estimated to have been infected with HIV in the U.S., and more than 1.1 
million are estimated to be living with HIV/AIDS today. Racial and 
ethnic minorities have been disproportionately affected by HIV/AIDS, 
and represent the majority of new AIDS cases (70%), new HIV infections 
(54%), prevalent HIV/AIDS cases (65%), and AIDS deaths (72%) (CDC, 
2006). African Americans have been especially affected by HIV/AIDS. 
More than half of all new HIV infections and half of new AIDS diagnoses 
occur in African Americans despite their accounting for approximately 
12% of the U.S. population. A similar impact exists among Latinos, who 
represent 14% of the U.S. population but account for 20% of estimated 
AIDS diagnoses. Together, Asian/Pacific Islanders and American Indian/
Alaska Natives represent 1%-2% of new AIDS diagnoses.
    The spread of HIV disease in the United States has been partly 
fueled by the use of illicit drugs. Injection drug use (IDU) is 
directly related to HIV transmission through the sharing of drug 
equipment. According to CDC's latest report on 2006 rates, IDUs 
accounted for 12 percent of estimated new HIV infections. CDC's 
historical trend analysis indicates that new infections have declined 
dramatically in this population over time and confirm the substantial 
evidence to date of success in reducing HIV infections among IDUs. 
Despite these declines, rates of HIV and AIDS continue to rise among 
certain groups including men who have sex with men, high risk 
heterosexual women and ethnic and racial minority groups due to non-IDU 
drugs and alcohol that interfere with judgment about sexual and other 
types of behaviors.
    The estimated hour burden is presented in the following table:

--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                             Number of      Responses/        Hours/        Total hour      Hourly wage     Total hour
                          Form                              respondents     respondent       response         burden         cost  ($)       cost  ($)
--------------------------------------------------------------------------------------------------------------------------------------------------------
MAI Rapid HIV Testing Clinical Information Form (at               20,000               1            .133           2,660           30.00          79,800
 Entry).................................................
MAI Rapid HIV Testing Clinical Information Form (second            4,000               1            .133             532           30.00          15,960
 test)..................................................
                                                         -----------------------------------------------------------------------------------------------
    Total...............................................          20,000  ..............  ..............           3,192  ..............          95,760
--------------------------------------------------------------------------------------------------------------------------------------------------------


[[Page 29495]]

    Written comments and recommendations concerning the proposed 
information collection should be sent by July 22, 2009 to: SAMHSA Desk 
Officer, Human Resources and Housing Branch, Office of Management and 
Budget, New Executive Office Building, Room 10235, Washington, DC 
20503; due to potential delays in OMB's receipt and processing of mail 
sent through the U.S. Postal Service, respondents are encouraged to 
submit comments by fax to: 202-395-6974.

    Dated: June 15, 2009.
Elaine Parry,
Director, Office of Program Services.
[FR Doc. E9-14556 Filed 6-19-09; 8:45 am]
BILLING CODE 4162-20-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.